Canada markets closed

Aprea Therapeutics, Inc. (APRE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.69+0.62 (+10.21%)
At close: 04:00PM EDT
6.50 -0.19 (-2.84%)
After hours: 06:43PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close6.07
Open5.92
Bid6.40 x 800
Ask6.30 x 900
Day's Range5.91 - 6.80
52 Week Range2.78 - 8.85
Volume28,419
Avg. Volume36,195
Market Cap24.998M
Beta (5Y Monthly)N/A
PE Ratio (TTM)0.54
EPS (TTM)12.31
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.67
  • GlobeNewswire

    Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

    First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in H1 2024. $21.6 million in cash and cash equivalents as of December 31, 2023 Private placement financing in March 2024 raised upfront gross proceeds of approximately $16 million DOYLESTOW

  • GlobeNewswire

    Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

    Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an additional $18.0 million in potential warrant exercise proceeds for an aggregate of up to $34.0 million in total gross proceeds DOYLESTOWN, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on

  • GlobeNewswire

    Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

    Company plans to initiate Phase 1 ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors, APR-1051) clinical trial evaluating, highly selective, oral WEE1 inhibitor, for monotherapy treatment of Cyclin E overexpressing cancers including breast and ovarian cancers Update from the ACESOT-1051 clinical trial expected in Q4 2024 DOYLESTOWN, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-